Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Arrowhead Pharmaceuticals ( (ARWR) ) has provided an announcement.
On January 12, 2026, Arrowhead Pharmaceuticals issued $700 million aggregate principal amount of 0.00% Convertible Senior Notes due 2032, including $75 million issued pursuant to the full exercise of the underwriters’ over-allotment option. The senior unsecured notes, which do not bear regular interest and mature on January 15, 2032, are convertible into Arrowhead common shares at an initial rate equivalent to a conversion price of about $87.07 per share, subject to customary adjustments and potential increases in certain make-whole scenarios, and include detailed provisions for redemption, repurchase upon fundamental changes, and events of default that govern creditor protections and the company’s capital structure. In connection with the notes offering, Arrowhead also entered into capped call transactions on January 7 and 8, 2026 with several financial institutions, spending approximately $47.9 million to economically hedge the conversion feature and reduce potential dilution to existing shareholders, with a cap price initially set at about $119.33 per share, thereby fine-tuning the balance between raising zero-coupon convertible financing and managing equity dilution risk.
The most recent analyst rating on (ARWR) stock is a Hold with a $68.00 price target. To see the full list of analyst forecasts on Arrowhead Pharmaceuticals stock, see the ARWR Stock Forecast page.
Spark’s Take on ARWR Stock
According to Spark, TipRanks’ AI Analyst, ARWR is a Neutral.
The score is driven by improving financial performance (positive EBITDA and cash flow with better leverage) and supportive earnings-call/corporate catalysts (FDA approval and large partnership-related payments). Offsetting factors are the still-unprofitable bottom line and limited valuation support (negative P/E/no dividend), with momentum constructive but not decisive.
To see Spark’s full report on ARWR stock, click here.
More about Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. is a biotechnology company focused on developing RNA interference-based therapeutics, with its common stock publicly traded and actively used in equity and convertible debt financing transactions.
Average Trading Volume: 2,589,467
Technical Sentiment Signal: Buy
Current Market Cap: $8.83B
For an in-depth examination of ARWR stock, go to TipRanks’ Overview page.